← All trials
NCT06569108
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2024
- Primary completion
- Oct 15, 2026
- Completion date
- Dec 15, 2026
- First posted
- Aug 23, 2024
- Last posted
- Aug 23, 2024
- Enrollment
- 111
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alphamab Co., Ltd.Lead sponsor
- Shandong Province Qianfoshan HospitalOfficial
- Henan Medical UniversityOfficial
- Hacettepe UniversityOfficial
- LanZhou UniversityOfficial
- Sichuan UniversityOfficial
- Henan Provincal People's HospitalOfficial
- China Medical UniversityOfficial
- Jinlin UniversityOfficial
- Nanchang UniversityOfficial
- Jiangxi Provincial People's HospitalOfficial
- Soochow UniversityOfficial
- North China University of Science and Technology Affiliated HospitalOfficial
- Jiao Tong UniversityOfficial
- Central South UniversityOfficial
- Capital Medical UniversityOfficial
- Capital Medical UniversityOfficial
- Wenzhou Medical UniversityOfficial
- Anhui Province Cancer HospitalOfficial
- Chongqing Medical UniversityOfficial
- Chinese Academy of Medical SciencesOfficial
- Chongqing Medical UniversityOfficial
- Kunming Medical UniversityOfficial
- Southern Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.